OmniAb (OABI) EBIT (2021 - 2026)
OmniAb (OABI) reported EBIT of -$7.8 million for Q1 2026, up 58.45% year-over-year from -$4.9 million in Q1 2025, and up 50.34% on a QoQ basis from -$15.8 million in Q4 2025.
OmniAb (OABI) has 6 years of EBIT data on file, last reported at -$7.8 million in Q1 2026.
- Quarterly EBIT rose 58.45% year-over-year to -$7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.0 million (up 18.14% YoY) and the FY2025 annual result came in at -$69.0 million, up 7.43% from the prior year.
- EBIT advanced to -$7.8 million in Q1 2026 per OABI's latest filing, from -$15.8 million in the prior quarter.
- Across five years, EBIT topped out at $9.0 million in Q4 2022 and bottomed at -$22.6 million in Q1 2024.
- The 5-year median for EBIT is -$16.2 million (2025), against an average of -$14.6 million.
- Peak annual rise in EBIT reached 125.54% in 2022, while the deepest fall reached 575002.97% in 2022.
- Tracing OABI's EBIT over 5 years: stood at $9.0 million in 2022, then slumped by 334.32% to -$21.2 million in 2023, then gained by 25.12% to -$15.9 million in 2024, then rose by 0.72% to -$15.8 million in 2025, then surged by 50.34% to -$7.8 million in 2026.
- Per Business Quant, the three latest OABI EBIT figures stand at -$7.8 million (Q1 2026), -$15.8 million (Q4 2025), and -$18.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | -7.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.83 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -16.22 Mn |
| Mar 31, 2025 | -18.84 Mn |
| Dec 31, 2024 | -15.88 Mn |
| Sep 30, 2024 | -19.76 Mn |
| Jun 30, 2024 | -16.31 Mn |
| Mar 31, 2024 | -22.55 Mn |
| Dec 31, 2023 | -21.21 Mn |
| Sep 30, 2023 | -20.32 Mn |
| Jun 30, 2023 | -19.45 Mn |
| Mar 31, 2023 | -8.45 Mn |
| Dec 31, 2022 | 9.05 Mn |
| Sep 30, 2022 | -14.91 Mn |
| Jun 30, 2022 | -12.57 Mn |
| Mar 31, 2022 | -8.22 Mn |
| Dec 31, 2021 | -35.43 Mn |
| Sep 30, 2021 | -170,579.00 |
| Jun 30, 2021 | -2,185.00 |
| Mar 31, 2021 | -7,786.00 |